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Abstract: The question as to why a protein exerts onco-
genic properties is answered mainly by well-established 
ideas that these proteins interfere with cellular signaling 
pathways. However, the knowledge about structural and 
functional peculiarities of the oncoproteins causing these 
effects is far from comprehensive. The 97.5% homologous 
tissue-specific A1 and A2 isoforms of mammalian trans-
lation elongation factor eEF1A represent an interesting 
model to study a difference between protein variants of 
a family that differ in oncogenic potential. We propose 
that the different oncogenic impact of A1 and A2 might be 
explained by differences in their ability to communicate 
with their respective cellular partners. Here we probed 
this hypothesis by studying the interaction of eEF1A with 
two known partners – calmodulin and actin. Indeed, 
an inability of the A2 isoform to interact with calmodu-
lin is shown, while calmodulin is capable of binding A1 
and interferes with its tRNA-binding and actin-bundling 
activities in vitro. Both A1 and A2 variants revealed actin-
bundling activity; however, the form of bundles formed in 
the presence of A1 or A2 was distinctly different. Thus, a 
potential inability of A2 to be controlled by Ca2+-mediated 
regulatory systems is revealed.
Keywords: actin bundling; calmodulin; higher eukaryotic 
elongation factors; protein-protein interaction.
Introduction
Translation elongation factor eEF1A plays a main role 
in ribosomal polypeptide synthesis while providing 
the delivery of aminoacyl-tRNAs to the ribosome A-site 
(Negrutskii and El’skaya, 1998; El’skaya et  al., 2013). 
This protein has also been shown to be multifunc-
tional and is known to be involved in a number of non- 
translational cellular processes (Ejiri, 2002; Lamberti 
et al., 2004; Abbas et al., 2015). Within mammalian cells 
there exist two isoforms of translation elongation factor 
that share 97.5% homology: eEF1A1 (A1) and eEF1A2 
(A2). The expression of the isoforms is tissue-specific 
(A2 is found in muscular, myocardial and neuronal 
tissue and in some specialized cells of pancreatic islet 
and gut) and mutually exclusive (Knudsen et al., 1993; 
Newbery et al., 2007); however, occasionally A2 appears 
also in the tissues where it is not expressed on a regular 
basis and this is thought to be related to tumor devel-
opment (Anand et al., 2002;  Tomlinson et al., 2005; Lee 
and Surh, 2009; Vislovukh et al., 2013; Xu et al., 2013; 
Kawamura et  al., 2014; Sun et  al., 2014; Yang et  al., 
2015). On the contrary, A1 is an ubiquitously and consti-
tutively expressed protein that is not oncogenic per se, 
despite the fact that its expression may be de-regulated 
in transformed cells and tissues (de Wit et  al., 2002; 
Mohler et al., 2002; Xie et al., 2002, also see for review 
 Scaggiante and Bosutti, 2015).
The mechanisms of oncogenic action of the A2 
isoform is mostly unknown, however, it is thought that 
A2 is involved in actin remodeling and enhanced cell 
migration and invasiveness in cancer cells (Amiri et al., 
2007). The apparent difference in the abilities of the 
two isoforms to interplay with cellular partners may 
be among main reasons of their different oncogenic 
impact.
Previous studies have shown that both the A1 and 
A2 isoforms exhibit variations in their spatial molecular 
organization (Novosylna et al., 2007; Kanibolotsky et al., 
2008), surface hydrophobicity and ability to form dimers 
(Timchenko et al., 2013) while the translational functions 
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of the A1 and A2 isoforms in vitro have been shown to be 
similar (Knudsen et  al., 1993; Timchenko et  al., 2013). 
Consequently, one may suggest that structural differences 
between the two isoforms may explain the observed dif-
ferences in the ability of the isoforms to interact with dif-
ferent non-translational protein partners. In this context, 
it may be useful to compare the ability of the two isoforms 
to bind two known partners of eEF1A, namely actin and 
calmodulin, and estimate the consequences of possible 
differences.
eEF1A of different origin is known to bind calmodulin 
in a Ca2+-dependent manner (Durso and Cyr, 1994; Kaur 
and Ruben, 1994; Kurasawa et al., 1996; Sengprasert et al., 
2015). Moreover, calmodulin binding can interfere with 
eEF1A-mediated effects on cytoskeleton rearrangements 
(Durso and Cyr, 1994; Moore et  al., 1998; Morita et  al., 
2008).
Also, eEF1A has been shown to bind and bundle 
actin filaments in vitro and enhance actin polymerization 
(Gross and Kinzy, 2005; Morita et al., 2008; Doyle et al., 
2011). The overexpression of eEF1A in yeast has been 
found to result in a slow growth phenotype and altered 
actin cytoskeleton organization in the absence of any 
measurable effects on protein synthesis (Gross and Kinzy, 
2005). Recently, the A1 isoform of mammalian eEF1A was 
shown to bind and bundle actin, supposedly due to a 
dimer formation (Vlasenko et  al., 2015). In contrast, no 
information on the ability of A2 to interact with actin is 
currently available.
Here we show that the oncogenic and tissue spe-
cific A2 isoform did not bind Ca2+-calmodulin. On the 
contrary, the A1 isoform readily interacted with Ca2+-
calmodulin in vitro. Moreover, endogenous calmodulin 
was precipitated by A1 from HEK293 cells. The domains 
of A1 involved into the interaction with Ca2+-calmodulin 
were predicted by calmodulin target database (Yap et al., 
2000) and confirmed experimentally. Functionally, Ca2+-
calmodulin displaced tRNA from the complex with A1 
and inhibited actin-bundling activity of the latter, which 
indicated a multipotent role of the calmodulin- mediated 
regulation of A1. We hypothesize that the exclusive 
expression of A2 in muscle, myocardium and neuronal 
tissues may be explained by the need to prevent the 
translation process from being exposed to quick changes 
in [Ca2+] observed in these tissues. Importantly, A1 and 
A2 induced the formation of actin bundles displaying 
distinctly different form. Thus, one cannot exclude the 
existence of an A2-specific effect on F-actin bundling in 
cancer tissues contributing to the tumor-specific actin 
cytoskeleton disorganization.
Results
Only isoform A1 interacts with Ca2+- 
calmodulin in vitro
Horizontal bidirectional polyacrylamide gel electropho-
resis under non-denaturing conditions was used for the 
electrophoretic mobility shift assay (EMSA) (Novosylna 
et al., 2015). This method proved to be quite  convenient 
and informative due to a significant difference in the 
molecular mass and the opposite surface charges of 
eEF1A and calmodulin. The eEF1A isoforms (∼50 kDa) 
have an isoelectric point about 9.0 and move towards the 
cathode, while calmodulin (17 kDa) has a pI of 4.0 and 
moves toward the anode. The eEF1A isoforms (2.8 µm) 
were titrated with increasing amounts of Ca2+- calmodulin. 
The complex of A1 and Ca2+-calmodulin started to form 
at a 1:3 ratio (mol/mol) (Figure 1A, lanes 1–4) while an 
analogous complex of A2 was not detected even at 30-fold 
molar excess of Ca2+-calmodulin (Figure 1A, lanes 5–8). 
Thus, there is a direct interaction of Ca2+-calmodulin with 
the A1 rather than A2 isoform.
The Ni-NTA pull down assay was performed to 
examine the possibility of interaction of endogenous 
calmodulin with stably expressing A1-His in HEK293 
cells. Importantly, this interaction was observed only in 
the presence of CaCl
2
 while the addition of EGTA com-
pletely abolished the complex formation (Figure 1B). 
Also, endogenous eEF1A1 and calmodulin were found to 
be co- localized in HEK293 cells (Supplementary material 
Figure S1).
Identification of calmodulin-binding sites in 
eEF1A1
To approach an explanation as to why the highly similar 
isoforms show a cardinally different ability to bind Ca2+-
calmodulin, the amino acid sequences of the proteins 
were analyzed using the calmodulin target database (Yap 
et  al., 2000). Indeed, a noticeable difference between 
the isoforms was found, namely the A1 isoform con-
tained an extended calmodulin binding site, compris-
ing two binding regions located in domain II (residues 
311–327) and domain III (residues 422–437). These regions 
are referred to as calmodulin binding site of domain 
II (CBSDII) and calmodulin binding site of domain III 
(CBSDIII). No CBSDII and only a shortened version of 
CBSDIII (residues 427–438) were predicted in the A2 
molecule (Figure  2A). This could explain the observed 
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difference between the interaction and non-interaction of 
A1 and A2 with calmodulin.
The location of the calmodulin-binding regions in A1 
was investigated experimentally using a pull-down assay 
with the GST-fusion constructs comprising domain I, 
domain (I + II) and domain (II + III) of A1 (Vlasenko et al., 
2015). Domain II and probably domain III of eEF1A1 were 
shown to bind calmodulin, which correlated well with 
Figure 1: eEF1A1-calmodulin complex formation.
(A) Non-denaturing polyacrylamide gel (7%) stained with Coomassie Brilliant Blue shows the complex of A1 with calmodulin and lack of such 
complex with A2. 2.8 µm eEF1A was mixed with 8 µm, 36 µm or 109 µm calmodulin in buffer containing 30 mm Tris, pH 7.5, 20% glycerol, 
1 mm MgCl
2
 and 6 mm 2-mercaptoethanol. Lanes: 1 – A1 alone; 2 – A1 and calmodulin (molar ratio 1:3); 3 – A1 and calmodulin (molar ratio 
1:13); 4 – A1 and calmodulin (molar ratio 1:40); 5 – A2 alone; 6 – A2 and calmodulin (molar ratio 1:3); 7 – A2 and calmodulin (molar ratio 
1:13); 8 – A2 and calmodulin (molar ratio 1:40). The eEF1A variants migrate towards the cathode (top of the gel) while calmodulin and the 
eEF1A-calmodulin complex migrate towards the anode (bottom of the gel). (B) A1 and calmodulin form the complex in the calcium dependent 
manner. The complex of His-tagged A1 and calmodulin was precipitated from HEK293 cell line stably expressing A1-His, using NiNTA resin. 
The resin was washed extensively, and then bound proteins were eluted by boiling in the Laemmli sample buffer. Samples were resolved by 
SDS-PAGE and visualized by immunoblotting with corresponding antibodies. One millimolar CaCl
2
 or 1 mm EGTA was added at every step of 
the assay. Non-transfected HEK293 lysates were used as control for non-specific binding to Ni-NTA resin (last two lines). Input – lysate of the 
same cells made in the presence of 1 mm CaCl
2
 or EGTA as indicated.
Figure 2: Identification of calmodulin-binding sites.
(A) Schematic representation of the A1 and A2 structures. Three known domains of eEF1A are marked I, II and III. The sequences of the predicted 
calmodulin interaction sites calculated by calmodulin target database engine, are indicated. (B) Binding of calmodulin to different domains of 
A1. Different GST-fused constructs coupled with glutathione sepharose beads were incubated with calmodulin, washed and eluted with 20 mm 
glutathione. Assays were performed in the buffer containing 1 mm CaCl
2
 (left panel) or 1 mm EGTA (right panel). D1 – domain 1 (1–243, 55 kDa), 
D1 + 2 – domain 1 + domain 2 (1–333, 64 kDa), D2 + 3 – domain 2 + domain 3 (244–462, 51 kDa). CaM – calmodulin control.
Brought to you by | Auburn University Main Campus
Authenticated
Download Date | 12/5/16 2:56 PM
116      O. Novosylna et al.: Comparison of eEF1A1 and eEF1A2
the bioinformatics prediction. This interaction was Ca2+-
dependent (Figure 2B, left panel), as the presence of EGTA 
precluded the complex formation (Figure 2B, right panel).
Modeling of the A1-Ca2+-calmodulin complex
As both bioinformatic and experimental data supported 
the involvement of CBSDII and CBSDIII in the interac-
tion of A1 with calmodulin, these epitopes were selected 
during the calmodulin receptor formatting for the mole-
cular docking. A1 was modeled by taking recently solved 
A2 crystal structure (Crepin et al., 2014) as a template. It 
should be noted that spatial structures of A1 and A2 in 
individual state, their hydrophobicity and ability to form 
dimers, may be different (Novosylna et  al., 2007; Kani-
bolotsky et al., 2008; Timchenko et al., 2013). A1 shows 
an extended conformation while A2 is a compact protein 
(Novosylna et  al., 2007; Kanibolotsky et  al., 2008). 
However, it is known that «extended» proteins, including 
A1, adopt a compact conformation upon interaction with 
a ligand (Budkevich et al., 2002; Shiau et al., 2006). That 
is why we believe the compact X-ray structure of eEF1A2 
may be used as an approximation to model the compact 
structure of eEF1A1 in the complex with calmodulin. As 
mentioned above, the minor amino acid substitutions 
in the CBSDII and CBSDIII sequences could be respon-
sible for the apparent inability of A2 to interact with 
calmodulin.
The complex of IQCG (IQ Motif Containing G) protein 
and Ca2+-bound calmodulin (PDB ID:4M1L) was chosen 
as a reference structure for the A1 docking to calmodu-
lin. The A1 model orientation was configured to be static, 
whereas the calmodulin molecule allowed rotating. 
Visual examination discovered a number of analogous 
complexes that could be divided into several groups: in 
the main groups A and B, the complexes approximated 
to the predictions from the bioinformatics studies. Group 
A showed one calmodulin molecule attached to both pre-
dicted binding sites in the eEF1A1*GDP molecule. A rep-
resentative model (complex #32) is shown in Figure 3A. 
In this complex, residues 315–323 created an interface 
between domain II of the A1 model and the C-terminal 
‘hand’ of calmodulin, which correlates well with the bio-
informatics prediction of CBSDII (Figure 2A) and earlier 
molecular dynamic simulation estimate (Kanibolotsky 
et  al., 2008). The bioinformatics prediction of CBSDIII 
also correlates with the docking model. The three resi-
dues (430-RQT-432) which are situated in the middle of 
CBSDIII create contacts with the opposite ‘hand’ of the 
calmodulin molecule. Importantly, the residues flanking 
the 430-RQT-432 region of CBSDIII do not appear to be 
exposed; being either covered by the Helix B of domain 
I or buried in domain III (like Phe424 and Val426). Some 
additional interacting clusters can be found in domain I, 
one of which is located near the conserved Thr72 residue 
from the SWITCH I region (Arg69 and Ile71). However, 
these contacts are probably rather weak as they are not 
important for the structural interaction (Figure 2B). The 
amount of residues that take part in the interface forma-
tion is 27 for eEF1A1 and 28 for calmodulin. The area of 
the interaction interface is 812.6 Å2. The degree of the 
interaction specificity (p-value) is 0.469, indicating that 
∆iG value is typical for this type of interface. We termed 
this model as the A1 mode of calmodulin binding.
Group B, representing nearly 25% of the complexes 
predicted by the docking, comprised the models where 
the calmodulin molecule was attached exclusively to the 
region of CBSDIII. In this case, one of the calmodulin ‘hand’ 
domains is bound while another is free. A representative 
model (complex #17) is shown in Figure 3B. This model is 
not supported by experimental data for eEF1A1, but it is of 
interest as it may correspond to  hypothetic A2-like way of 
binding, as according to calmodulin target database, A2 
may have a single and reduced  calmodulin-binding site in 
domain III (Figure 2A).
As the A1 and A2 molecules can exist in dimeric form 
(Timchenko et al., 2013; Crepin et al., 2014) and the dimers 
were suggested to be of functional importance (Bunai 
et al., 2006; Migliaccio et al., 2015; Vlasenko et al., 2015) it 
was estimated whether calmodulin binding in the A1 or A2 
mode can interfere with the dimer formation (Figure 3C). 
Interestingly, CBSDIII is buried inside the dimer, so in this 
case the interaction of calmodulin with this site seems 
impossible. Consequently, it may prevent the interac-
tion of the A2 dimer with calmodulin, as CBSDIII is the 
only interaction site predicted for A2. At the same time, 
CBSDII, present exclusively in the A1 structure, remains 
totally exposed in the dimer. Thus, it is possible, that 
in the A1 dimer one ‘hand’ of the calmodulin molecule 
binds to CBSDII first, and then dissociation of the dimer 
is induced, which makes CBSDIII exposed and available 
for binding by another ‘hand’ of the calmodulin molecule.
Calmodulin interferes with tRNA-binding 
activity of eEF1A1
One of the ways calmodulin interferes with cellular pro-
cesses is through its direct binding to target proteins. As 
there is an obvious difference between the A1 and onco-
genic A2 isoforms in their ability to bind Ca2+-calmodulin, 
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it is important to estimate a potential functional role of 
the specific A1-calmodulin interaction. First, we assessed 
the potential of calmodulin to interfere with translation 
elongation catalyzed by A1. As the location of the pre-
dicted calmodulin-binding site of A1 gained experimental 
support, it appeared important to estimate how it may 
overlap with the A1 sites of interaction with translational 
partners like tRNA. These interaction sites were deduced 
from the crystal structures of the corresponding complexes 
(PDB ID: 1b23, 1F60) (Nissen et al., 1999; Andersen et al., 
2000; Soares et al., 2009). Indeed, an overlap of the calm-
odulin and tRNA interaction sites in the A1 molecule was 
found (Figure 4A). To examine experimentally, whether 
this apparent overlap in binding sites results in compe-
tition between calmodulin and tRNA, the complex of A1 
with [32P]-tRNALeu was formed and titrated with increasing 
concentrations of Ca2+-calmodulin (Figure  4B). EMSA in 
native gel was used to follow the reaction course. A1 and 
tRNA form a strong complex that does not enter native gel, 
therefore it is not visible on the autoradiograph. In this 
case, only a small amount of free tRNA is seen (Figure 
4B, upper panel, lane 5). Upon addition of calmodulin, 
the intensity of the bands corresponding to free tRNA 
increases sharply, indicating that calmodulin ousts tRNA 
from the complex with A1. This can be observed at equi-
molar calmodulin: A1 ratio (Figure 4B, upper panel, lanes 
Figure 3: Possible interaction modes of the A1 or A2 isoforms with Ca2+-calmodulin.
(A) The eEF1A1-calmodulin complex interaction model with calmodulin bound to both predicted sites within domains II and III. eEF1A1 is 
in grey and its domains are labeled. Calmodulin is in red. (B) The eEF1A2 interaction model with calmodulin bound to only one predicted 
site within domain III with one ‘head’ on a loose. eEF1A2 is in grey and its domains are labeled. Calmodulin is in red. (C) CBSDII rather than 
CBSDIII is exposed in the dimeric structure of eEF1A. On the left is dimer, on the right is monomer. In the dimer, one eEF1A molecule is 
colored grey and another is colored brown. CBSDII is in blue, CBSDIII is in green.
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6–12). The interaction of calmodulin with A1 is reflected 
by the inverse relationships between the calmodulin 
concentration rise and the decreasing A1 band intensity 
(Figure 4B, bottom panel, lanes 6–12). Thus, a competition 
between calmodulin and tRNA for A1 is possible and this 
may interfere with the translational activity of the latter.
We were also interested to determine whether the 
presence of calmodulin would affect the ability of A1 
to bind guanine nucleotide (Supplementary material 
Figure  S2). The presence of calmodulin (even at 10-fold 
excess) had no effect on spontaneous GDP exchange in 
the A1 molecule. This data correlates with the lack of 
interaction between nucleotide binding of domain D1 and 
calmodulin, which was shown both experimentally and 
through bioinformatics studies.
A1 and A2 generate actin bundles that have 
different morphology
Another established binding partner of eEF1A is actin. The 
comparison of the A1 and oncogenic A2 interaction with 
F-actin is of importance, as the changes in the regulation of 
the cytoskeleton are often involved in cancer development 
and metastatic transformation (Rao and Li, 2004; Amiri 
et al., 2007; Mouneimne et al., 2012; Fife et al., 2014). To 
examine possible differences in the actin bundling capa-
bilities of A1 and A2, atomic force and confocal micros-
copy were carried out. Results showed a pronounced 
effect of both isoforms on the formation of F-actin bundles 
(Figure 5A and B). For AFM, similar results were obtained 
using different substrates including mica (Figure 5A) and 
graphite (data not shown).
Contrary to A1, short, thick, splinter-like bundles 
were formed in the presence of the oncogenic A2 isoform 
(Figure 5B). As the formation of actin bundles is most 
probably triggered by the dimers of eEF1A (Vlasenko et al., 
2015), the difference in the appearance of actin bundles 
may be explained by the recent finding that the A2 dimers 
are essentially more compact than that of A1 (Timchenko 
et al., 2013).
Calmodulin negatively influences 
 actin-bundling activity of A1
As Ca2+-calmodulin was reported to inhibit sea urchin 
and Tetrahymena eEF1A-catalyzed actin bundling (Morita 
et al., 2008; Fujimoto and Mabuchi, 2010), we used this 
model to examine the ability of calmodulin to interfere 
with actin bundling induced by mammalian A1. Figure 5C 
shows that Ca2+-calmodulin negatively influenced actin 
bundling by A1, suggesting an impact of Ca2+-calmodulin 
on the non-translational functions of A1.
It should be noted that some inhibitory effect of 
Ca2+-calmodulin on the A2-induced actin bundling in 
vitro was also observed (data not shown). The reasons 
for this remain unclear, as calmodulin does not interact 
with A2 (Figure 1A) and actin (data not shown) in vitro. 
As mentioned above, the existence of some calmodulin 
binding site was predicted in domain III of A2 (Figure 
2A and B). As domain III of eEF1A is also responsible for 
actin binding (Vlasenko et  al., 2015) some competition 
may exist between calmodulin and actin for monomeric 
A2 and this may explain this result. However, as shown 
Figure 4: Calmodulin can interfere with translation function of A1.
(A) The tRNA and calmodulin binding sites in eEF1A partially overlap. The location of the tRNA-binding site (left panel) marked red and 
calmodulin-binding site (right panel) marked blue is shown in the yeast eEF1A crystal structure (PDB ID: 1F60). (B) Calmodulin ousts [32P]-
tRNALeu from the complex with A1. Upper panel: autoradiograph of the gel. Bottom panel: gel shift assay of A1, calmodulin and radiolabeled 
tRNALeu. Coomassie Brilliant Blue staining.
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in Figure 1A, the extended and potent calmodulin binding 
site of eEF1A1 provides much more efficient binding of the 
ligand than the severely reduced analogous site in the A2 
molecule.
Thus, one may suggest a potential role of calmodulin 
in both translation and non-translational functions of A1 
rather than A2.
Discussion
The intriguing tumor-inducing appearance of the A2 
variant of translation elongation factor 1 in ovary cancer 
was detected over a decade ago (Anand et al., 2002). Since 
then, the A2 isoform has been found in a number of differ-
ent human cancer tissues and evidence for its oncogenic 
role obtained (Abbas et al., 2015). Recently, it was found 
that the induction of non-specific expression of A2 in 
tumors might result from the loss of microRNA-mediated 
control (Vislovukh et  al., 2013). The 97.5% homologous 
A1 and A2 isoforms were described to possess differ-
ent shapes in solution, different hydrophobic properties 
and ability to form dimers (Timchenko et al., 2013). X-ray 
structure of eEF1A2*GDP was recently published (Crepin 
et  al., 2014) while the A1 isoform could not be crystal-
lized, supposedly due to its ‘extended’ conformation 
Figure 5: Actin-bundling activity of the eEF1A isoforms.
(A) AFM tapping mode image of F-actin stabilized with phalloidin (left panel), F-actin bundled in the presence of A1 (central panel) or A2 
(right panel). Height image, mica substrate. (B) Confocal microscope images of F-actin: phalloidin-stabilized F-actin filaments (left panel), 
F-actin bundling in the presence of A1 (central panel) or A2 (right panel). All images were captured using a 63 ×  oil immersion lens. (C) Effect 
of calmodulin on the actin bundle formation induced by A1. Low-speed actin co-sedimentation assay. Nine micromolar actin was prepared 
as described in Materials and Methods and mixed with 9 µm A1 and 13 µm calmodulin in the presence of 1 mm CaCl
2
 or 1 mm EGTA. The 
supernatants (S) and pellets (P) were analysed by SDS-PAGE stained with Coomassie Brilliant Blue. The bands corresponding to A1, actin 
and calmodulin are shown by arrows.
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(Budkevich  et  al., 2002). The question as to why A2 
revealed oncogenic properties still remains unanswered.
We reason that differences in the structural proper-
ties of the isoforms might provide a basis for their differ-
ent interactions with protein partners, including those 
involved in signaling and maintaining cell shape, which, 
in turn, might contribute to oncogenesis. To investigate 
this possibility in principle, we used two known protein 
partners of eEF1A, calmodulin and actin. Intriguingly, 
the oncogenic A2 isoform has revealed much less ability 
to bind calmodulin as compared to A1. In line with that, 
our preliminary studies suggest that contrary to A1, A2 
does not bind S100A6, which is a disparate member of 
the family of Ca2+-related proteins (Novosylna, Filipek 
and Negrutskii, unpublished observation). Recent data 
reported the inability of A2 rather than A1 to form a 
complex with co-chaperone Sgt1, which plays a role in 
cell division (Novosylna et al., 2015). On the other side, A2 
showed increased, as compared to A1, ability to interact 
with SH2 and SH3 domains of different signaling mole-
cules in vitro (Panasyuk et al., 2008). However, the analy-
sis of published phosphoproteomics data suggested that 
the tyrosine residues, which are readily phosphorylated 
in A1, are not modified in the A2 isoform in cancer tissues 
(Negrutskii et al., 2012).
Thus, our own data and that reported within the lit-
erature lead us to assume that the A2 isoform may be less 
important (compared to A1) for Ca2+-modulated cellular 
control and which may make translation less prone to 
the conditions of permanent changes in Ca2+ concentra-
tions in muscle, myocardial and neuronal tissues, where 
A2 is expressed as the only eEF1A isoform (Knudsen 
et al., 1993; Lee et al., 1993). However, the expression of 
A2 can be sporadically induced in the tissues where the 
only A1 isoform is present normally (Anand et al., 2002; 
Lee, 2003; Li et  al., 2006; Zhu et  al., 2007; Cao et  al., 
2009; Lee and Surh, 2009; Vislovukh et  al., 2013). In 
such tissues, newly appeared A2 can escape A1-adapted 
regulation and act in an uncontrolled way, thus acquir-
ing oncogenic properties. Possible regulatory mecha-
nisms involved will be a subject of further investigations. 
We believe that the actin-bundling role of A2 should be 
specially considered as cancer-related one, because the 
dysregulated actin bundling may play a key role in meta-
static processes (Hashimoto et al., 2007; Stevenson et al., 
2012).
A role of A1 under conditions of dysregulation of 
calmodulin amount or Ca2+ flux in the cells could be also 
essential as these conditions may influence the amount of 
‘free’ A1 protein, thus having an impact on its functionally 
important re-distribution to different translational and 
non-translational compartments (Sasikumar et  al., 2012; 
Abbas et al., 2015).
A number of the paralogue protein families have 
been described recently, where one representative of a 
family was oncogenic while another was not (Kim et al., 
2009; Lau et al., 2012; Huang et al., 2014;  Samyesudhas 
et  al., 2014; Sirianant et  al., 2014). It is known that 
minimal changes in the amino acid sequence and/or 
post- translational modification status of a protein may 
lead to total rearrangement of its conformation and mul-
timeric state (Alexander et  al., 2007, 2009; Khan et  al., 
2013) which may be the case of eEF1A2. The paralogues 
may differ in post-translational modifications (Tossidou 
et al., 2012; Guo et al., 2015; Werner et al., 2015), reveal 
distinct tissue expression (Kim et  al., 2009; Samyesud-
has et  al., 2014), cellular localization (Sirianant et  al., 
2014), and functions (Bai et  al., 2011; Palmer et  al., 
2012; Wanitchakool et  al., 2014; Fu et  al., 2016). Unfor-
tunately, fundamental basis for this metamorphosis, 
which could be a different ability of the variants to inter-
act with diverse cellular partners (Jacobsen et al., 2010) 
remains mostly unexplored. Generalizing our data, one 
may suggest that in some cases, subtle changes in the 
amino acid sequences of ‘oncovariant’ paralogues make 
their conformation less suitable for interactions with 
cellular partners compared to their counterparts. Thus, 
cellular contacts of oncoproteins can be modified or 
even eliminated, as compared to normal paralogues. 
This effect may be caused by the substitution of amino 
acids directly involved in protein-ligand interactions, as 
well as the substitutions of amino acids, which are post-
translationally modified in one of the variants.
Materials and methods
Materials
The eEF1A isoforms (more than 90% purity) was isolated from rab-
bit liver or muscles as described (Shalak et al., 1997; Lukash et al., 
2004; Yaremchuk et al., 2012). The rabbit skeletal muscle actin was 
purchased from Cytoskeleton, Inc. (Denver, USA). The protein was 
reconstituted, according to the manufacturer’s instructions. Before 
each experiment, actin was incubated on ice for 60 min followed 
by centrifugation at 16 000 g for 15 min. The plasmids coding for 
recombinant domains of Homo sapiens eEF1A1: D1 (1–243), D1 + D2 
(1–333), D2 + D3 (244–462) were generously gifted by C. Knudsen. 
The domains were expressed as the GST-fusion proteins in E. coli 
and puriied with glutathione sepharose 4B beads from GE Health-
care Life Sciences (Little Chalfont, UK) according to the manu-
facturer’s instructions. [P32]-labelled tRNALeu was kindly gifted by 
Dr. Futernyk.
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Puriication of calmodulin
All procedures, except high-temperature treatment and phenyl-sepha-
rose chromatography, were carried out at +4°C. Cow brain (∼350  g) 
was grinded and homogenized in two volumes of homogenization 
bufer [50 mm Tris-HCl pH 7.5, 2 mm 2-mercaptoethanol, 1 mm EDTA, 
0.5 mm phenylmethylsulfonyl luoride (PMSF)] for 1 min. Homogen-
ate was centrifuged 40 min at 14 000 g. The supernatant was passed 
through four layers of cheesecloth. Then (NH4)
2
SO
4
 was added at con-
stant stirring to 60% saturation (36.6 g/100 ml of the supernatant). pH 
of solution was adjusted to 4.1 with 6 m acetic acid. After formation of 
the precipitate for at least 2 h, the proteins were recovered by centrifu-
gation for 30 min at 14 000 g. The pellet was dissolved in a minimal 
volume of bufer containing 50 mm Tris-HCl pH 7.5, 2 mm 2-mercaptoe-
thanol. pH was adjusted to 7.5 with 1 m Tris solution and centrifuged 
again under the same conditions to remove insoluble proteins. The 
resulting supernatant was incubated in small portions (∼30 ml) for 
5 min in a boiling bath and cooled in ice. Heat denatured protein was 
removed by 60 min centrifugation at 2000 g. Chromatography on phe-
nyl-sepharose was carried out at room temperature. One molar CaCl
2
 
was added to supernatant to a 5 mm inal concentration and applied 
to phenyl sepharose CL-4B column, equilibrated with bufer contain-
ing 50 mm Tris-HCl pH 7.5, 2 mm 2- mercaptoethanol, 0.1 mm CaCl
2
. 
Unbound proteins were washed out with the same bufer and then 
with the same bufer containing 0.5 m NaCl. Calmodulin was eluted 
with bufer containing 50 mm Tris-HCl pH 7.5, 2 mm 2-mercaptoetha-
nol, 3 mm EGTA. Then, calmodulin was concentrated on Q-sepharose 
and dialyzed against bufer containing 25 mm Tris-HCl pH 7.5, 10% 
glycerol, 6 mm 2-mercaptoethanol.
Electrophoretic mobility shift assay (EMSA)
Horizontal non-denaturing gel electrophoresis was carried out as 
described in Novosylna et al. (2015). Before running, the samples were 
incubated for 10 min at 37°C in the binding bufer containing 30 mm 
Tris-HCl, pH 7.5, 20% glycerol, 1 mm MgCl
2
, 6 mm 2- mercaptoethanol 
and 1 mm CaCl
2
. After electrophoresis, the gel was stained with 
Coomassie Brilliant Blue. In the experiments using radiolabeled 
tRNA, the gel was dried before autoradiograph was captured.
SDS-PAGE and Western blotting
Gel electrophoresis in 15% (w/v) polyacrylamide containing 0.1% SDS 
(SDS-PAGE) was performed as described (Laemmli, 1970). Separated 
proteins were electrotransferred onto nitrocellulose membrane and 
identiied using mouse monoclonal anti-eEF1A from Merck Millipore 
(Billerica, USA) diluted 1:5000, rabbit monoclonal anti-calmodulin 
from Novus Biologicals, (Cambridge, UK) diluted 1:5000 or mouse 
polyclonal anti-GST antibody (home-made, kindly provided by 
Dr. O. Gorbenko, IMBG, diluted 1:500). After washing with PBST (PBS 
plus 0.1% Tween-20) blots were incubated with secondary antibodies 
(goat anti-mouse HRP-conjugated antibody (1:10 000) from Amersham 
Biosciences (Amersham, UK), anti-rabbit HRP-conjugated antibody 
(1:10 000, Amersham Biosciences) and goat anti-mouse IgG antibod-
ies conjugated to horseradish peroxidase (1:10 000) (Merck Millipore). 
Blots were developed with the ECL kit (Amersham Biosciences).
His-tag pull-down assay
The protein lysates of HEK293 cells overexpressing eEF1A1-His were 
prepared in the lysis bufer containing 50 mm Tris-HCl pH 7.5, 100 mm 
NaCl, 10 mm imidazole and the cocktail of protease inhibitors from 
Roche (Basel, Switzerland). Then the lysates were centrifuged at 
14 000 g for 20 min. The supernatant fractions were applied to the Ni-
NTA resin equilibrated with the lysis bufer. The resin was incubated 
1 h at 4°C with agitation and washed sequentially with wash bufer 
I (50 mm Tris-HCl pH 7.5, 300 mm NaCl, 10 mm imidazole) and wash 
bufer II (50 mm Tris-HCl pH 7.5, 500 mm NaCl, 20 mm imidazole). 
The carrier was equilibrated with binding bufer (50 mm Tris-HCl pH 
7.5, 100 mm NaCl) supplemented with 1 mm CaCl
2
 or 1 mm EGTA. The 
samples were incubated 1 h at 4°C with agitation and washed with 
the same bufer. Bound proteins were eluted with the SDS sample 
bufer and analyzed by SDS-PAGE.
GST pull-down assay
Puriied calmodulin was dialyzed against bufer containing 30 mm 
Tris-HCl, pH 7.5, 20% glycerol, 1 mm MgCl
2
, 6 mm 2-mercaptoethanol) 
supplemented with 1 mm CaCl
2
 or 1 mm EGTA and incubated with GST 
or GST-fusion domains of A1 bound to the glutathione beads. The 
Sepharose was washed with the the same bufer three times. Samples 
were eluted from the resin with the elution bufer (20 mm reduced 
glutathione, 50 mm Tris-Cl, pH 8.0). Calmodulin was detected with 
anti-calmodulin antibodies (Novus Biologicals).
Actin-bundling assay
The efect of calmodulin on actin bundle formation was examined 
using the low-speed actin co-sedimentation assay as described pre-
viously (Vlasenko et  al., 2015). A1 and calmodulin were dialyzed 
against bufer containing 30 mm Tris-HCl, pH 7.5, 20% glycerol, 1 mm  
MgCl
2
, 6 mm 2-mercaptoethanol. Actin (9 µm) was prepared as 
described above and incubated with A1 (9 µm) and calmodulin (13 µm) 
in a total volume of 25 µl for 30 min at room temperature. The volume 
of each sample was adjusted with the same bufer. The mixture was 
supplemented with 50 mm KCl, 2 mm MgCl
2
 and 1 mm ATP. The sam-
ples were centrifuged at 16 000 g for 15 min. The supernatants and 
pellets were solubilized in the SDS-PAGE sample bufer and analyzed 
by SDS-PAGE, with subsequent Coomassie Blue staining.
Actin-bundling microscopy studies
Atomic force microscopy: Imaging of F-actin in the presence and 
absence of eEF1A was carried out using atomic force microscopy 
(AFM) as described previously by (Doyle et  al., 2011). Briely, actin 
was polymerized and eEF1A added in 5:1 actin: A1 or A2 ratio. Next, 
the actin:eEF1A was deposited onto mica or graphite substrates, left 
to air-dry at ambient temperature and imaged using atomic micros-
copy. AFM images were obtained using a Molecular Force Probe-3D 
(MFP-3D) atomic force microscope (Asylum Research, Goleta, USA) 
operated in AC mode using Olympus AC240 cantilevers.
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Confocal microscopy: F-Actin was prepared as described above 
using a 5:1 actin:eEF1A1 or eEF1A2 ratio and labeled with Acti-stain 
488 Phalloidin (Cytoskeleton Inc.) according to the manufacturer’s 
instructions. All confocal microscopy images were captured with a 
Zeiss LSM510 confocal microscope. For imaging Phalloidin-labelled 
actin an argon-ion laser (488  nm excitation) was used. All images 
were captured using a 63 ×  oil immersion lens.
Computer modeling and docking procedures
eEF1A1 homology modeling was performed using MODELLER (Sali 
and Blundell, 1993) online service hosted by the UCSF RBVI. Crys-
tal structure of mammalian eEF1A2 (PDB ID:4C0S) was used as a 
template. UCSF Chimera 1.10.2 (Pettersen et  al., 2004) provided a 
graphical interface to running the program MODELLER online. 
Molecular docking was performed in Molsoft ICM Pro 3.8-3 software 
(Abagyan et  al., 1994). The calculation algorithm is based on the 
all-atom vacuum force ield ECEPP/3, taking into account solvation 
free energy and entropic contribution. Conformational sampling 
is based on the biased probability Monte Carlo (BPMC) procedure 
with random selection of a certain conformation in the internal 
coordinate space, with sequential shift to a new random position 
independent of the previous position but according to a predeined 
continuous probability distribution. For each state, additional full 
local minimization was performed. Rendering of images for illus-
trations was performed in UCSF Chimera 1.10.2. (Pettersen et  al., 
2004).
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